What's breaking now, across thousands of outlets.
(MedPage Today) -- Taking the nonhormonal dual neurokinin (NK) receptor antagonist elinzanetant (Lynkuet) at bedtime did not result in residual daytime sleepiness and actually improved sleepiness scores in postmenopausal women, according to a pooled...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.
When DNA is damaged, cellular processes respond and repair the DNA. Inhibiting DNA damage repair can be therapeutically beneficial in cancers with genetic vulnerabilities related to DNA damage…
Researchers have developed a fiber that functions as pixels and senses touch at the same time.
Bristol Myers Squibb is facing one problem after another with its autoimmune CAR-T therapy program. The company says it has figured out the cause of the safety signal in a lupus trial ...
Most new cancer medicines approved by European regulators over a recent four-year period do not offer high clinical benefit, a new analysis finds.
(MedPage Today) -- You passed medical training, now see if you can pass our weekly quiz
Where should the safety bar be for studies investigating CAR-T therapies for autoimmune conditions?
